TauRx's HMTM could be the first anti-tau disease-modifying d

TauRx announced topline results from its Phase III LUCIDITY trial evaluating its oral anti-tau product, hydromethylthionine mesylate.

Related Keywords

China , Germany , Italy , Japan , United Kingdom , France , Spain , Sisacorn Shutterstock , Electronic Data Capture Solutions For Clinical Trials , Sample Services , Alzheimer Neuroimaging Initiative , Cold Chain Storage Solutions For Pharmaceutical Products , Clinical Trials , Disease Assessment Scale , Neuroimaging Initiative , Data Capture Solutions , Clinical Supply , Biological Sample , Chain Storage Solutions ,